

The convergence of genomic medicine and translational omics in transforming breast cancer patient care

Sulin Wu,¹ Yonglan Zheng,^{1,2} and Olufunmilayo I. Olopade^{1,2}

¹Section of Hematology and Oncology, Department of Medicine and ²Center for Clinical Cancer Genetics & Global Health, Department of Medicine, The University of Chicago, Chicago, Illinois, USA.

Introduction

Breast cancer is the most diagnosed cancer among women worldwide, with an estimated 2.3 million new cases and 670,000 deaths reported in 2022 (1). Advances in genomic research have heralded a new era in precision medicine, enabling personalized treatment and risk assessment based on molecular profiles. Next-generation sequencing and deep-learning (DL) algorithms have transformed breast cancer care by facilitating the analysis of complex and extensive datasets, with the potential to democratize access to omics-informed clinical trials.

A comprehensive understanding of the heterogeneity and complexity of breast cancer across diverse populations, along with intricate disease mechanisms, is fueling innovations aimed at personalizing breast cancer care and reducing global disparities in outcomes.

Navigating heterogeneity to optimize therapeutics

For decades, the treatment of breast cancer has been based on classification according to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status (2–5). However, advances in genomics technologies have underscored the critical role of molecular profiling in determining prognosis and guiding treatment strategies. For patients with early stage breast cancer, genomic information enables more accurate predictions of recurrence and metastasis risk, identifies molecular subtypes of the disease, and helps prevent overtreatment by refining traditional therapeutic approaches (Table

1). Furthermore, discovering pathogenic variants in *BRCA1* DNA repair associated (*BRCA1*) and *BRCA2* genes has been pivotal to our understanding of both hereditary and sporadic breast cancers. These variants largely increase breast and ovarian cancer risks and identify patients who may benefit from targeted therapies like poly (ADP-ribose) polymerase (PARP) inhibitors. The OlympiA trials have shown that olaparib effectively reduces recurrence risk in patients with *BRCA*-mutated breast cancer, an example of enhanced outcomes through personalized care for high-risk individuals (6). For hormone receptor-positive (HR⁺) breast cancers, the addition of CDK4/6 inhibitors to hormonal therapies offers a more potent treatment, particularly for patients with high disease burden or progression on prior endocrine therapy. Selective ER degraders are a class of drugs representing a substantial advance in treating HR⁺ breast cancers by effectively degrading ER and inhibiting tumor growth. In contrast, HER2-positive breast cancers, known for their aggressive behavior, respond favorably to targeted therapies such as trastuzumab, pertuzumab, and tyrosine kinase inhibitors.

Recent innovations in antibody-drug conjugates (ADCs), such as trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have notably improved survival outcomes for HER2-positive patients (7, 8). The FDA approval of T-DXd for unresectable or metastatic HER2-positive cases underscores the critical role of genomic and molecular profiling in treatment decisions. While these advances herald a promising future for breast cancer therapy, especially for a recently defined subset of HER2-low

breast cancer, the challenge of broadening access to these drugs for rare subtypes of breast cancer remains. Triple-negative breast cancer (TNBC) is a particularly aggressive disease with limited treatment options. Immunotherapeutic agents like pembrolizumab have expanded treatment possibilities for PD-(L)1-positive TNBC, offering new hope for patients, though further research is needed to fully evaluate their impact (9). The development of Trop2-based ADCs also holds promise for improving TNBC outcomes (10). Applying artificial intelligence (AI) and DL algorithms to analyze the tumor microenvironment (TME) can substantially enhance ADC development by identifying therapeutic targets and optimizing antibody design. Integrating genetic, pharmacogenomic, and histopathologic data can further improve the selection of antibody targets and cytotoxic payloads, making ADCs more versatile therapeutic options across multiple cancer types.

Precision medicine for breast cancer

Precision oncology integrated with germline genetic testing has transformed breast cancer care by revealing the genetic underpinnings of disease development, recurrence risk, and treatment resistance. These advances facilitate more personalized cancer treatments tailored to each patient's unique genetic and molecular profiles.

A milestone in the molecular characterization of breast cancer was the discovery of the *BRCA1* and *BRCA2* genes. *BRCA1* pathogenic variants, enriched in basal-like/TNBC, and the epigenetic silencing of *BRCA1*, which impairs DNA repair, play significant roles in cancer progression (11). The advancement of polygenic risk scores (PRSs) based on breast cancer genetic variants identified by GWAS allows for more personalized breast cancer

Conflict of interest: OIO serves on the advisory boards for CancerIQ and Tempus.

Copyright: © 2024, Wu et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: *J Clin Invest*. 2024;134(21):e187520. <https://doi.org/10.1172/JCI187520>.

Table 1. Genetic testing in breast cancer care

Assay type	Oncotype Dx	MammaPrint	Prosigna (PAM50)	Breast cancer index (BCI)
Clinical trial	TAILORx	MINDACT	TransATAC	Trans-aTTom
Genetic test	21 genes (16 cancer related, 5 reference)	70 genes	50 genes	11 genes
Clinical application	Predicts risk of recurrence; Benefit of chemotherapy	Predicts risk of distant metastasis	Predicts risk of recurrence; Intrinsic subtype classification (luminal A, luminal B, HER2-enriched, basal like)	Predicts risk of early and late recurrence; Benefit of extended endocrine therapy
Subtype assessed	HR ⁺ HER2 ⁻	HR ⁺ HR ⁻ HER2 ⁻ HER2 ⁺	HR ⁺ HER2 ⁻	HR ⁺ HER2 ⁻
Risk classification	Low, intermediate, high	Low, high	Low, intermediate, high	Low, intermediate, high; H/I ratio for late recurrence
Approval and guideline status	FDA approved, included in clinical guidelines	FDA approved, included in clinical guidelines	FDA cleared, included in clinical guidelines	Included in clinical guidelines

Dx, diagnosis; H/I, *HOXB13/IL17BR*.

screening, which supports early detection and efficient prevention strategies (12–14). Integrating genomic, epigenomic, and pseudogene expression data with clinical features holds promise for developing precise prognostic models to personalize treatment and accelerate progress in prevention and early detection, with potential to reduce disparities in breast cancer outcomes when appropriately deployed for population health management (15).

Given the paucity of omics data from non-European ancestry populations, large datasets from initiatives such as The Cancer Genome Atlas and the International Cancer Genome Consortium have provided comprehensive catalogs of genomic aberrations that inform clinical management and precision medicine. The genomic landscape of breast cancer is notably heterogeneous, including mutations, copy number variations, and structural alterations that affect tumor progression and treatment response (16). Advances in high-throughput sequencing and computational biology have identified differences in genomic alterations associated with aggressive breast cancer progression and metastasis in diverse populations. Notable findings in the mutational landscape include the mutually exclusive presence of *GATA3* and *TP53/PIK3CA* pathogenic variants, higher levels of intratumoral heterogeneity, and genomic instability in breast cancer among Nigerian women, as well as the discovery of a unique breast cancer subtype defined by early clonal pathogen-

ic variants in *GATA3* and a younger age at diagnosis (17). The *TP53* gene is the most frequently mutated in breast cancer, particularly in TNBC and HER2-positive subtypes. Patients with *TP53*-mutant breast cancer typically face a higher risk of recurrence, poorer overall survival, and a greater likelihood of metastasis compared with those with wild-type *TP53*. There is an urgent need to identify upstream lifestyle and environmental risk factors for specific mutational signatures. Various clinical trials currently explore WEE1 and MDM2/MDMX inhibitors for *TP53*-mutated cancers. Additionally, *PIK3CA* pathogenic variants, common in HR⁺ breast cancers, activate the PI3K/AKT/mTOR pathway and are effectively targeted by alpelisib combined with endocrine therapy. Mutations in other genes, such as *PTEN*, *AKT1*, and *ESR1*, guide the development of novel inhibitors and combination therapies to overcome resistance mechanisms.

While genomics offers insights into mutations and genetic variability, proteomics translates these changes into the biological mechanisms that drive cancer progression, drug resistance, and treatment response. Initiatives like the Clinical Proteomic Tumor Analysis Consortium significantly enhance our understanding of genetic alterations at the protein level. Integrative approaches, including digital pathology, provide a comprehensive view of the molecular landscape, fostering the creation of highly effective, individualized treatment strategies. Modern techniques

now allow for the simultaneous assessment of multiple biomarkers, revealing complex interactions within the TME. These advances will be crucial for developing personalized treatments, deepening our understanding of cellular diversity and refining prognostic and predictive assessments, ultimately improving therapies and biomarker development in the future (18).

Advancing biomarker development with AI and DL

AI-based imaging algorithms and DL models enhance the accuracy and efficiency of cancer detection, assisting radiologists in identifying breast lesions (19). AI also automates breast-density assessments, enabling earlier diagnosis and intervention. By integrating imaging data with patient-specific omics profiles, computational methods can aid in developing personalized treatment plans (20). AI could offer high accuracy in classifying cancerous tissues, underscoring its critical role in diagnostic precision and tailored treatments (21). Furthermore, radiogenomics links imaging features with genetic mutations to predict molecular pathway activity and optimize treatment. For example, tumor texture heterogeneity on imaging can indicate *ERBB2* amplification, guiding the use of trastuzumab or pertuzumab and highlighting the importance of the TME.

The TME, composed of a diverse array of cell types in a dynamic and intricate structure surrounding the tumor, plays a critical role in immune modulation, mak-

ing it a crucial target for advancing more effective immunotherapeutic strategies. Alterations in the TME can influence the release of tumor-derived materials, including circulating tumor cells, cell-free DNA, and exosomes, into the bloodstream. Analyzing these components provides valuable insights into tumor dynamics and treatment response. Liquid biopsy, utilizing advanced cell identification and single-cell sequencing, serves as a noninvasive tool to track disease progression and detect resistance mutations with high sensitivity and specificity. For example, detecting *ESR1* mutations in HR⁺ breast cancer can predict resistance to aromatase inhibitors, guiding a switch to therapies such as fulvestrant.

Challenges and opportunities

Breast cancer presents a complex landscape for precision medicine, with challenges arising from the disease's intricacies and the advanced technologies required to address them. Precision medicine, grounded in genetic insights, offers promise, through integrating germline and somatic profiling to guide treatment decisions. Additionally, genetic testing raises ethical concerns, such as incidental findings and potential privacy issues, requiring education for healthcare providers and an informed public to participate in innovative clinical trials.

Despite these challenges, AI-based integrative research and advanced computational methods offer potential approaches to identify novel biomarkers and optimize breast cancer treatment regimens. Innovative clinical trial designs, such as platform and basket studies, enable validation of these biomarkers. Technologies such as single-cell RNA sequencing pro-

vide deeper insights into TME heterogeneity and resistance mechanisms. The convergence of AI, genomics, immunotherapy, and digital pathology is set to revolutionize breast cancer treatment, paving the way for more personalized and effective therapies. Key to our success will be high quality cancer care powered by affordable access to health insurance, innovative clinical trial design, and community-engaged research so that every person has a fighting chance to survive and thrive after a diagnosis of breast cancer, the most common female cancer in the world.

Acknowledgments

This work was supported by an NIH grant (R01 MD013452 to OIO) and a Susan G. Komen grant (SAC210203 to OIO).

Address correspondence to: Olufunmilayo I. Olopade, 5841 S. Maryland Avenue, MC 2115, Chicago, Illinois 60637, USA. Phone: 773.702.1632; Email: folopade@medicine.bsd.uchicago.edu.

- Rindi G, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. *Endocr Pathol.* 2022;33(1):115–154.
- Horwitz KB, McGuire WL. Specific progesterone receptors in human breast cancer. *Steroids.* 1975;25(4):497–505.
- McGuire WL. Estrogen receptors in human breast cancer. *J Clin Invest.* 1973;52(1):73–77.
- Slamon DJ, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science.* 1989;244(4905):707–712.
- Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest.* 2011;121(7):2750–2767.
- Tutt ANJ, et al. Adjuvant olaparib for patients with *BRCA1*- or *BRCA2*-mutated breast cancer. *N Engl J Med.* 2021;384(25):2394–2405.
- von Minckwitz G, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *N Engl J Med.* 2019;380(7):617–628.
- André F, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. *Lancet.* 2023;401(10390):1773–1785.
- Schmid P, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. *N Engl J Med.* 2022;386(6):556–567.
- Bardia A, et al. Datopotamab deruxtecan in advanced or metastatic HR⁺/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. *J Clin Oncol.* 2024;42(19):2281–2294.
- van 't Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature.* 2002;415(6871):530–536.
- Mars N, et al. Comprehensive inherited risk estimation for risk-based breast cancer screening in women. *J Clin Oncol.* 2024;42(13):1477–1487.
- Zhang H, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nat Genet.* 2020;52(6):572–581.
- Roberts E, et al. Polygenic risk scores and breast cancer risk prediction. *Breast.* 2023;67:71–77.
- Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA.* 2006;295(21):2492–2502.
- Huo D, et al. Comparison of breast cancer molecular features and survival by African and European ancestry in the cancer genome atlas. *JAMA Oncol.* 2017;3(12):1654–1662.
- Ansari-Pour N, et al. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. *Nat Commun.* 2021;12(1):6946.
- Marotta LLC, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24[−] stem cell-like breast cancer cells in human tumors. *J Clin Invest.* 2011;121(7):2723–2735.
- Niazi MKK, et al. Digital pathology and artificial intelligence. *Lancet Oncol.* 2019;20(5):e253–e261.
- Sammut S-J, et al. Multi-omic machine learning predictor of breast cancer therapy response. *Nature.* 2022;601(7894):623–629.
- Howard FM, et al. The impact of site-specific digital histology signatures on deep learning model accuracy and bias. *Nat Commun.* 2021;12(1):4423.